Oncomine Clinical Research
Grant Program Awardees



2022 Oncomine Grant Awardees


Matias Avila, B. Pharm., Ph.D

Carmen Berasain, Ph.D

University of Navarra, Pamplona, Spain

“Mutational Analysis of Bile cfDNA for the Early Diagnosis of Biliopancreatic Tumors”


Wendy Erber, MD

The University of Western Australia, Crawley, Australia

“Genomic Profiling and Disease Monitoring Using Plasma Cell-Free DNA in Acute Myeloid Leukemia”


Xiuning Le, MD, PhD

MD Anderson Cancer Center, Houston, U.S.A.

“ctDNA Analysis to Understand Resistance and Response to ORC Therapy in EGFR Mutant Non-Small Cell Lung Cancer”


Nir Peled, MD, PhD, FCCP

Dr. Laila C. Roisman

Shaare Zedek Medical Center, Jerusalem, Israel

“Liquid Biopsy in Suspected Lung Cancer Solitary Pulmonary Nodules”


Dr. Monica Lopez-Guerra, PhD

Hospital Clinic, Barcelona, Spain

“Molecular measurable residual disease (MRD) monitoring by high-throughput techniques in patients with CART 19 therapy”


Prof. Estrid Høgdall, PhD

Herlev University Hospital, Herlev, Denmark

“HRD biomarker: Qualification and implementation of validated local HRD test”


Prof. Dr. Paul Hofman, PhD

University of Côte d’Azur, France

“Comprehensive molecular characterization of early stage NSCLC with KRAS G12C mutation using ODxET”

2021 Oncomine Grant Awardees


Myungshin Kim, MD

Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

“Prognostic value of minimal residual disease monitoring by comprehensive next-generation sequencing in pediatric acute myeloid leukemia”


Tarek Bismar, MD

University of Calgary Cumming School of Medicine, Canada

“Characterizing Prostate Cancer Plasticity Relative to Lethal Disease, Neuroendocrine Differentiation and Therapeutic Resistance”


Fernando López-Ríos, MD, PhD

Esther Conde, MD, PhD

Susana Hernández Prieto, PhD

Department of Pathology
"12 de Octubre" University Hospital
Madrid, Spain

“Ultrafast next generation sequencing: Universal Testing Of Patients with Infiltrating Adenocarcinomas of the Lung”


Wolfram Jochum, MD

Cantonal Hospital St. Gallen, Switzerland

“Homologous recombination deficiency (HRD) testing in high-grade serous carcinoma using peritoneal effusion samples”


Elin Gray, PhD

Edith Cowan University, Australia

“TCR repertoire in combination with HLA and TMB as predictor of response to immune checkpoint blockade in melanoma and lung cancer”


Elena Guerini Rocco, MD

European Institute of Oncology IRCCS, Italy

“Dissecting the tumor immune microenvironment of breast cancer during pregnancy”


Harriet Wikman, PhD

University Hospital Hamburg-Eppendorf, Germany

“Analyses of the role of immune-host cell interactions in defining different brain metastases patterns in NSCLC”


Dirce Carraro, PhD

AC Camargo Cancer Center, Brazil

"Predictive biomarker for metastatic melanoma patients treated with immune checkpoint inhibitors"


Beatriz Bellosillo, PhD

Edurne Arriola, MD, PhD

Hospital del Mar, Spain

Head Researchers:
Beatriz Bellosillo - Head of Molecular Diagnostics Section, Pathology Department
Edurne Arriola - Head of the Thoracic and Genitourinary Section

“Receiving the grant from Thermo Fisher to assess the role of liquid biopsy in Small cell Lung cancer will allow to discover novel biomarkers and therapeutic avenues in a disease with urgent clinical needs.”


Giulia Siravegna, PhD

Harvard Medical School

Head Researcher:
Giulia Siravegna, PhD - Instructor in Medicine Harvard Medical School, Department of Medicine, Research staff, Massachusetts General Hospital Cancer Center

“This grant will allow the characterization of circulating free tumor DNA (ctDNA) isolated from ascites fluid in gastric cancer patients and its comparison it with matched peripheral blood ctDNA, as well as primary tumor samples to identify peritoneal/ascites-specific targets. The use of ascitic fluid as a source for predictive and prognostic biomarkers is itself highly innovative and allows for rapid clinical translation as material is routinely sampled in clinical care.”


Leomar Y. Ballester, MD, PhD

The University of Texas Health Science Center at Houston

Head Researcher:
Leomar Ballester - Assistant Professor, Molecular Genetic Pathology and Neuropathology
Co-Director, Molecular Diagnostics Laboratory, Department of Pathology and Laboratory Medicine, Department of Neurosurgery

“The Oncomine Clinical Research Grant will facilitate our development of a cerebrospinal fluid liquid biopsy assay to incorporate precision medicine strategies in the management of patients with primary and metastatic central nervous system tumors. The Genexus System could provide the necessary sensitivity and specificity to enhance current methods for evaluating the potential of targeted therapies for patients.”


Stephen Fox, PhD

Peter MacCallum Cancer Centre

Head Researcher:
Professor Stephen Fox - Director of Pathology and Head of the Molecular Pathology Laboratory, at Peter Mac in Melbourne, Australia

"This grant will enable us to provide circulating tumour (ct) DNA testing to patients with non-small cell lung cancer in rural and remote parts of Victoria, Australia, where outcomes are poorer for this cancer. We will be able to rapidly identify mutations in ctDNA and deliver coordinated specialized oncology care to these patients. The goal is to determine whether liquid biopsies can replace tumour biopsies for selecting patients for the most appropriate treatment."

2020 Oncomine Grant Awardees


Kojo S. Elenitoba-Johnson  

University of Pennsylvania, USA

“Clinical validation of a rapid NGS-based molecular screening assay for myeloid neoplasms”


Sibylle Madlener

Medical University of Vienna, Austria

“New detectable targets in liquid biopsy samples of pediatric
brain tumors”


Brandon Sheffield

W. Osler Health System, Canada

“Rapid in-house comprehensive genomic profiling to guide community oncology practice”


Elaine Leung - Andrew Beggs

University of Birmingham, UK

“Evaluation of the prognostic and predictive significance of fusion genes in epithelial ovarian cancer”

Contact Us

For any questions about the Oncomine Clinical Research Grant Program, please email medical.affairs@thermofisher.com